Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated NSCLC By Ogkologos - September 10, 2026 80 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes MOST POPULAR Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast... October 25, 2022 Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC June 1, 2022 FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole... October 28, 2024 First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor... September 20, 2020 Load more HOT NEWS Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in cHL Tarlatamab Shows Promise in Patients with Previously Treated Small-Cell Lung Cancer
